Torstein Baade RÃ,

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4913140/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting phosphoglycerate dehydrogenase in multiple myeloma. Experimental Hematology and Oncology, 2021, 10, 3.	5.0	12
2	Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. , 2020, 8, e000610.		70
3	Registerâ€based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016. Acta Paediatrica, International Journal of Paediatrics, 2019, 108, 699-706.	1.5	0
4	Considering formulation characteristics when prescribing and dispensing medicinal products for children: a qualitative study among GPs and pharmacists. Family Practice, 2019, 36, 351-356.	1.9	2
5	Fear of hypoglycaemia and its relation to hypoglycaemia awareness and symptom intensity in Type 1 diabetes. Diabetes Research and Clinical Practice, 2018, 137, 213-220.	2.8	8
6	Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration. Experimental Hematology and Oncology, 2018, 7, 8.	5.0	10
7	Requests for new oral antibiotic prescriptions in children within 2 days: a Norwegian population-based study. Family Practice, 2018, 35, 690-697.	1.9	8
8	Strategies parents use to give children oral medicine: a qualitative study of online discussion forums. Scandinavian Journal of Primary Health Care, 2017, 35, 221-228.	1.5	14
9	Reduced Th22 cell proportion and prevention of atopic dermatitis in infants following maternal probiotic supplementation. Clinical and Experimental Allergy, 2017, 47, 1014-1021.	2.9	46
10	Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration. Journal of Translational Medicine, 2016, 14, 71.	4.4	26
11	Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer Journal, 2014, 4, e196-e196.	6.2	45
12	PRL-3 Mediates Survival of Primary Myeloma Cells. Blood, 2014, 124, 2040-2040.	1.4	0
13	Anti â€∢scp>MET Nanobody [®] – a new potential drug in multiple myeloma treatment. European Journal of Haematology, 2013, 91, 399-410.	2.2	40
14	HGF and IGF-1 synergize with SDF-1 $\hat{1}$ ± in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Experimental Hematology, 2013, 41, 646-655.	0.4	26
15	High expression of <i>BCL3</i> in human myeloma cells is associated with increased proliferation and inferior prognosis. European Journal of Haematology, 2009, 82, 354-363.	2.2	32
16	Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica, 2008, 93, 619-622.	3.5	40
17	A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells. Clinical Cancer Research, 2004, 10, 6686-6694.	7.0	83